Finally, patients with myelodysplastic syndromes (MDS) presenting with monosomy 7 (where EZH2 is located) or inactivating point mutations of EZH2 respond better to treatment with 5‐azacytidine, suggesting that dual inhibition of EZH2 and DNA methylation might be more effective in these patients (Tobiasson et al., 2016). Here, EZH2 is linked to myelodysplastic syndrome.